Beihua Kong

4.3k total citations
121 papers, 3.1k citations indexed

About

Beihua Kong is a scholar working on Reproductive Medicine, Molecular Biology and Obstetrics and Gynecology. According to data from OpenAlex, Beihua Kong has authored 121 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Reproductive Medicine, 42 papers in Molecular Biology and 34 papers in Obstetrics and Gynecology. Recurrent topics in Beihua Kong's work include Ovarian cancer diagnosis and treatment (50 papers), Endometrial and Cervical Cancer Treatments (29 papers) and Endometriosis Research and Treatment (13 papers). Beihua Kong is often cited by papers focused on Ovarian cancer diagnosis and treatment (50 papers), Endometrial and Cervical Cancer Treatments (29 papers) and Endometriosis Research and Treatment (13 papers). Beihua Kong collaborates with scholars based in China, United States and Sweden. Beihua Kong's co-authors include Wenxin Zheng, Oluwole Fadare, Xiang Li, Xingsheng Yang, Ruifen Dong, Jie Jiang, Wenxin Zheng, Qifeng Yang, Fei Zhao and Chunping Qiu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Beihua Kong

116 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beihua Kong China 32 1.2k 1.2k 796 685 611 121 3.1k
Ivo Meinhold‐Heerlein Germany 27 800 0.6× 956 0.8× 589 0.7× 407 0.6× 528 0.9× 133 2.5k
Dan‐Arin Silasi United States 30 1.1k 0.9× 591 0.5× 503 0.6× 747 1.1× 1.2k 1.9× 85 3.0k
Masanori Kaneuchi Japan 32 1.2k 1.0× 1.0k 0.9× 1.4k 1.8× 692 1.0× 642 1.1× 92 3.3k
Hanbyoul Cho South Korea 26 1.2k 1.0× 362 0.3× 295 0.4× 598 0.9× 1.1k 1.8× 94 2.7k
Stefania Cosio Italy 36 729 0.6× 1.7k 1.5× 1.5k 1.9× 375 0.5× 893 1.5× 118 3.4k
Agustin A. García United States 31 1.1k 0.9× 836 0.7× 363 0.5× 392 0.6× 1.5k 2.5× 114 3.1k
J. J. Kavanagh United States 32 859 0.7× 1.2k 1.0× 728 0.9× 181 0.3× 879 1.4× 95 3.0k
Yasunobu Kanamori Japan 26 1.0k 0.8× 573 0.5× 408 0.5× 452 0.7× 1.1k 1.8× 72 2.5k
Ilan Bruchim Israel 24 916 0.7× 498 0.4× 393 0.5× 463 0.7× 646 1.1× 101 2.2k
Thomas L. Klug United States 19 991 0.8× 1.9k 1.6× 482 0.6× 274 0.4× 640 1.0× 33 3.5k

Countries citing papers authored by Beihua Kong

Since Specialization
Citations

This map shows the geographic impact of Beihua Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beihua Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beihua Kong more than expected).

Fields of papers citing papers by Beihua Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beihua Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beihua Kong. The network helps show where Beihua Kong may publish in the future.

Co-authorship network of co-authors of Beihua Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Beihua Kong. A scholar is included among the top collaborators of Beihua Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beihua Kong. Beihua Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kong, Beihua, et al.. (2025). Mirvetuximab soravtansine: current and future applications. Journal of Hematology & Oncology. 18(1). 33–33. 4 indexed citations
2.
Shen, Yuanming, Beihua Kong, Bairong Xia, et al.. (2023). Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial.. Journal of Clinical Oncology. 41(16_suppl). 5556–5556. 1 indexed citations
3.
Xie, Lin, Ran Chu, Kai Wang, et al.. (2020). Prognostic Assessment of Cervical Cancer Patients by Clinical Staging and Surgical-Pathological Factor: A Support Vector Machine-Based Approach. Frontiers in Oncology. 10. 1353–1353. 17 indexed citations
4.
Sun, Xiaomei, Samina Dongol, Chunping Qiu, et al.. (2018). miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer. Molecular Cancer Research. 16(12). 1927–1939. 66 indexed citations
5.
Zhang, Qing, Yinuo Li, Yuqiong Wang, et al.. (2018). Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma. Cancer Letters. 432. 144–155. 40 indexed citations
6.
Qiu, Chunping, Nan Lü, Xiao Wang, et al.. (2017). Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. Gynecologic Oncology. 147(3). 634–641. 16 indexed citations
7.
Huang, Zhen, Kun Song, Xing Sheng Yang, et al.. (2017). Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer. Medicine. 96(42). e7935–e7935. 19 indexed citations
8.
Li, Yinuo, Shu‐Hua Lu, Ying Xu, et al.. (2017). Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma.. PubMed. 9(6). 2901–2910. 65 indexed citations
9.
Zhang, Yun, Jintang Sun, Lei Zhao, et al.. (2015). Human trophoblast cells induced MDSCs from peripheral blood CD14+ myelomonocytic cells via elevated levels of CCL2. Cellular and Molecular Immunology. 13(5). 615–627. 38 indexed citations
10.
Xie, Qi, et al.. (2013). Expansion of decidual CD45RO+ T cells with high expression of CEACAM1 in the early stage of pregnancy. Molecular Medicine Reports. 8(2). 571–578. 2 indexed citations
11.
Li, Jie, Yan Ning, Nisreen Abu Shahin, et al.. (2013). Secretory cell expansion with aging: Risk for pelvic serous carcinogenesis. Gynecologic Oncology. 131(3). 555–560. 23 indexed citations
12.
Wang, Yue, Yiying Wang, Jie Li, et al.. (2013). PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. Journal of Hematology & Oncology. 6(1). 60–60. 23 indexed citations
13.
Liang, Fei, Jie Zhou, Vladimir M. Popov, et al.. (2012). Increased Expression of Dachshund Homolog 1 in Ovarian Cancer as a Predictor for Poor Outcome. International Journal of Gynecological Cancer. 22(3). 386–393. 14 indexed citations
14.
Jia, Lin, Xiaofang Yi, Zhiyue Zhang, et al.. (2011). Prohibitin as a novel target protein of luteinizing hormone in ovarian epithelial carcinogenesis. Neoplasma. 58(2). 104–109. 13 indexed citations
15.
Zheng, Wenxin, Xiang Li, Oluwole Fadare, & Beihua Kong. (2010). A Proposed Model for Endometrial Serous Carcinogenesis. The American Journal of Surgical Pathology. 35(1). e1–e14. 70 indexed citations
16.
Zhang, Xi, Sharon X. Liang, Lin Jia, et al.. (2009). Molecular Identification of “Latent Precancers” for Endometrial Serous Carcinoma in Benign-Appearing Endometrium. American Journal Of Pathology. 174(6). 2000–2006. 23 indexed citations
17.
Song, Kun, et al.. (2007). Intraperitoneal photodynamic therapy for an ovarian cancer ascite model in Fischer 344 rat using hematoporphyrin monomethyl ether. Cancer Science. 98(12). 1959–1964. 33 indexed citations
18.
Miao, Qing & Beihua Kong. (2006). [A case-control study on etiology of epithelial ovarian cancer in Shandong Province].. PubMed. 25(7). 871–5. 5 indexed citations
19.
Kong, Beihua, Shengdong Huang, Winston Wang, et al.. (2005). Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. International Journal of Gynecological Cancer. 15(5). 872–877. 2 indexed citations
20.
Kong, Beihua, et al.. (2004). [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].. PubMed. 39(6). 390–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ivo Meinhold‐Heerlein Breakdown of academic impact, for papers by Dan‐Arin Silasi Breakdown of academic impact, for papers by Masanori Kaneuchi Breakdown of academic impact, for papers by Hanbyoul Cho Breakdown of academic impact, for papers by Stefania Cosio Breakdown of academic impact, for papers by Agustin A. García Breakdown of academic impact, for papers by J. J. Kavanagh Breakdown of academic impact, for papers by Yasunobu Kanamori Breakdown of academic impact, for papers by Ilan Bruchim Breakdown of academic impact, for papers by Thomas L. Klug
Rankless by CCL
2026